EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Safety and effectiveness of tofogliflozin in Japanese people with type 2 diabetes: A multicenter prospective observational study in routine clinical practice

Yuichiro Yamada iD, Daisuke Yabe iD, Kenichiro Shide, Atsushi Suzuki, Yasuo Terauchi, Yasunori Sato, Nobuyuki Shihara, Yutaka Seino iD

Journal of Diabetes Investigation · 2024

DOI: 10.1111/jdi.14287 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Diabetes Investigation, 2024. Verfasst von Yuichiro Yamada und 7 weiteren Autor:innen. Beteiligte Einrichtung: Japan Association for Diabetes Education and Care, Tokyo, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucosides, Benzhydryl Compounds, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Kowa Company, Ltd, Kowa Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims/Introduction Sodium–glucose cotransporter 2 (SGLT2) inhibitors effectively and safely reduce fasting and postprandial hyperglycemia while promoting weight loss. However, their unique mechanism of action contributes to concerns regarding their safety. We therefore carried out a large‐scale, non‐commercial, investigator‐initiated study on the safety and effectiveness of the SGLT2 inhibitor tofogliflozin. Materials and Methods This multicenter, open‐label, uncontrolled, prospective observational study was carried out at hospitals and clinics across Japan in participants aged ≥20 years who were SGLT2 inhibitor‐naïve and had an established diagnosis of type 2 diabetes. The primary endpoint was adverse drug reactions (ADRs) of special interest. Secondary endpoints included all other ADRs and adverse events, glycated hemoglobin (HbA1c), and weight loss. Results The study, carried out from June 2014 through February 2020, enrolled 11,480 participants from 1,103 medical institutions; 6,967 participants completed the 104‐week follow up. The most common ADRs of special interest were urinary and genital tract infections (1.53%), followed by volume depletion (1.25%). Hypoglycemia occurred in 27 participants (0.24%), adverse events in 1,054 (9.18%) and ADRs in 645 (5.62%). HbA1c decreased by 0.85% (95% confidence interval 0.82%–0.88%) and bodyweight decreased by 3.05 kg (95% confidence interval 2.94–3.17 kg). The HbA1c target was achieved by 51.70% of participants for target HbA1c

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2GlucosidesBenzhydryl CompoundsSodium-Glucose Transporter 2 InhibitorsGlycated HemoglobinHumansMaleFemaleProspective StudiesMiddle AgedJapanAgedBlood GlucoseAdultTreatment OutcomeHypoglycemic AgentsFollow-Up StudiesEast Asian People

Stichwörter der Autor:innen

Glycemic managementType 2 diabetesWeight loss

Substanzen

Glucosides6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-1(3H),2'-(2H)pyran)-3',4',5'-tri…Benzhydryl CompoundsSodium-Glucose Transporter 2 InhibitorsGlycated Hemoglobinhemoglobin A1c protein, humanBlood GlucoseHypoglycemic Agents

Autor:innen und Institutionen

  • Japan Association for Diabetes Education and Care, Tokyo, Japan.
  • Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kyoto, Japan.
  • Kansai Electric Power Hospital, Osaka, Japan.
  • Department of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.
  • Center for One Medicine Innovative Translational Research, Gifu University, Gifu, Japan.
  • Department of Metabolism and Clinical Nutrition, Kyoto University Hospital, Kyoto, Japan.

ORCID-Profile: Yuichiro Yamada, Daisuke Yabe, Yutaka Seino

Förderung

  • Kowa Company, Ltd
  • Kowa Company

Zitieren

APA

Yamada, Y., Yabe, D., Shide, K., Suzuki, A., Terauchi, Y., Sato, Y., Shihara, N., & Seino, Y. (2024). Safety and effectiveness of tofogliflozin in Japanese people with type 2 diabetes: A multicenter prospective observational study in routine clinical practice. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.14287

Vancouver

Yamada Y, Yabe D, Shide K, Suzuki A, Terauchi Y, Sato Y, et al. Safety and effectiveness of tofogliflozin in Japanese people with type 2 diabetes: A multicenter prospective observational study in routine clinical practice. Journal of Diabetes Investigation. 2024. doi:10.1111/jdi.14287

BibTeX
@article{Yamada2024,
  author = {Yamada, Yuichiro and Yabe, Daisuke and Shide, Kenichiro and Suzuki, Atsushi and Terauchi, Yasuo and Sato, Yasunori and Shihara, Nobuyuki and Seino, Yutaka},
  title = {Safety and effectiveness of tofogliflozin in Japanese people with type 2 diabetes: A multicenter prospective observational study in routine clinical practice},
  journal = {Journal of Diabetes Investigation},
  year = {2024},
  doi = {10.1111/jdi.14287}
}
Kostenlos starten →